RxDoctor Payments Data

Hung-Yin Yeh

Nurse Practitioner · Mountain View, CANPI 1982171278

Payments from drug & device makers

$1,258in general payments, 2019–2025

Across 74 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$367
  • Amgen$210
  • Novo Nordisk$188
  • Boehringer Ingelheim$135
  • Insulet Corporation$131
  • Abbott$62
  • plus $163 from 6 others

What the payments were for

  • Food & beverage$1,24699%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,258 in reported general payments places this provider in the 80th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$47,114
Medicare patients
134
Services billed
527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide143$246,702
MounjaroTirzepatide73$108,126
JardianceEmpagliflozin79$106,829
TrulicityDulaglutide39$73,160
Synjardy XrEmpagliflozin/Metformin Hcl20$33,366
JanuviaSitagliptin Phosphate22$32,814
TradjentaLinagliptin19$15,507
Lantus SolostarInsulin Glargine,hum.Rec.Anlog78$13,124
Tresiba Flextouch U-100Insulin Degludec14$11,260
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp18$11,127
Humalog Kwikpen U-100Insulin Lispro37$10,617
Testosterone44$8,128
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$6,346
Nano 2nd Gen Pen NeedlePen Needle, Diabetic60$5,359
HumalogInsulin Lispro12$3,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$188$246,702143 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$367$184,566124 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$135$155,702118 claims
MerckJanuvia$57$32,81422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Mountain View

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →